Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...

Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership in progressive pulmonary fibrosis (PPF). The ...

Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team of Columbia and UCSD ...

A recent study revealed that early-life exposure to tobacco significantly elevates the risk of developing idiopathic ...

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause of bacterial pneumonia for them. Indeed, it was the most frequently isolated ...

Two companies have come together to enhance the way imaging technology is used to assess treatment responses in progressive ...

A transatlantic Cambridge2Cambridge alliance between Qureight in the UK and Avalyn Pharma Inc in Massachusetts – is seeking ...

An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

AdAlta’s lead product, AD-214, is a first in class, next generation antibody therapeutic for the treatment of fibrotic ...

Inhibition of BRSK2 attenuated lung fibrosis in cellular and animal models, identifying it as a potential therapeutic target for IPF.

This clinical trial aimed to determine whether Thal can stop the progression of fibrosis in IPF patients (“Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide”). It was conducted between 2005 ...